These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15816854)

  • 1. CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model.
    Chou SY; Lee YC; Chen HM; Chiang MC; Lai HL; Chang HH; Wu YC; Sun CN; Chien CL; Lin YS; Wang SC; Tung YY; Chang C; Chern Y
    J Neurochem; 2005 Apr; 93(2):310-20. PubMed ID: 15816854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system.
    Chiang MC; Chen HM; Lai HL; Chen HW; Chou SY; Chen CM; Tsai FJ; Chern Y
    Hum Mol Genet; 2009 Aug; 18(16):2929-42. PubMed ID: 19443488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opposite effects of the A2A receptor agonist CGS21680 in the striatum of Huntington's disease versus wild-type mice.
    Martire A; Calamandrei G; Felici F; Scattoni ML; Lastoria G; Domenici MR; Tebano MT; Popoli P
    Neurosci Lett; 2007 Apr; 417(1):78-83. PubMed ID: 17331645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of CGS 21680, a selective adenosine A(2A) receptor agonist, on NMDA receptor function and expression in the brain of Huntington's disease mice.
    Ferrante A; Martire A; Armida M; Chiodi V; Pézzola A; Potenza RL; Domenici MR; Popoli P
    Brain Res; 2010 Apr; 1323():184-91. PubMed ID: 20138162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms.
    Bailey CD; Johnson GV
    J Neurochem; 2005 Jan; 92(1):83-92. PubMed ID: 15606898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impaired glucose tolerance in the R6/1 transgenic mouse model of Huntington's disease.
    Josefsen K; Nielsen MD; Jørgensen KH; Bock T; Nørremølle A; Sørensen SA; Naver B; Hasholt L
    J Neuroendocrinol; 2008 Feb; 20(2):165-72. PubMed ID: 18034868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease.
    Ju TC; Chen HM; Chen YC; Chang CP; Chang C; Chern Y
    Biochim Biophys Acta; 2014 Sep; 1842(9):1668-80. PubMed ID: 24946181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphodiesterase type IV inhibition prevents sequestration of CREB binding protein, protects striatal parvalbumin interneurons and rescues motor deficits in the R6/2 mouse model of Huntington's disease.
    Giampà C; Middei S; Patassini S; Borreca A; Marullo F; Laurenti D; Bernardi G; Ammassari-Teule M; Fusco FR
    Eur J Neurosci; 2009 Mar; 29(5):902-10. PubMed ID: 19291221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global changes to the ubiquitin system in Huntington's disease.
    Bennett EJ; Shaler TA; Woodman B; Ryu KY; Zaitseva TS; Becker CH; Bates GP; Schulman H; Kopito RR
    Nature; 2007 Aug; 448(7154):704-8. PubMed ID: 17687326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation.
    Zourlidou A; Gidalevitz T; Kristiansen M; Landles C; Woodman B; Wells DJ; Latchman DS; de Belleroche J; Tabrizi SJ; Morimoto RI; Bates GP
    Hum Mol Genet; 2007 May; 16(9):1078-90. PubMed ID: 17360721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lentiviral gene delivery of GDNF into the striatum of R6/2 Huntington mice fails to attenuate behavioral and neuropathological changes.
    Popovic N; Maingay M; Kirik D; Brundin P
    Exp Neurol; 2005 May; 193(1):65-74. PubMed ID: 15817265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of tetrathiomolybdate in the R6/2 model of Huntington disease.
    Tallaksen-Greene SJ; Janiszewska A; Benton K; Hou G; Dick R; Brewer GJ; Albin RL
    Neurosci Lett; 2009 Mar; 452(1):60-2. PubMed ID: 19429000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IGF-1 protects against diabetic features in an in vivo model of Huntington's disease.
    Duarte AI; Petit GH; Ranganathan S; Li JY; Oliveira CR; Brundin P; Björkqvist M; Rego AC
    Exp Neurol; 2011 Oct; 231(2):314-9. PubMed ID: 21763311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice.
    Domenici MR; Scattoni ML; Martire A; Lastoria G; Potenza RL; Borioni A; Venerosi A; Calamandrei G; Popoli P
    Neurobiol Dis; 2007 Nov; 28(2):197-205. PubMed ID: 17720507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA microarray analysis of striatal gene expression in symptomatic transgenic Huntington's mice (R6/2) reveals neuroinflammation and insulin associations.
    Crocker SF; Costain WJ; Robertson HA
    Brain Res; 2006 May; 1088(1):176-86. PubMed ID: 16626669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The R6 lines of transgenic mice: a model for screening new therapies for Huntington's disease.
    Gil JM; Rego AC
    Brain Res Rev; 2009 Mar; 59(2):410-31. PubMed ID: 19118572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington's disease.
    Petersén A; Chase K; Puschban Z; DiFiglia M; Brundin P; Aronin N
    Exp Neurol; 2002 May; 175(1):297-300. PubMed ID: 12009780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained striatal ciliary neurotrophic factor expression negatively affects behavior and gene expression in normal and R6/1 mice.
    Denovan-Wright EM; Attis M; Rodriguez-Lebron E; Mandel RJ
    J Neurosci Res; 2008 Jun; 86(8):1748-57. PubMed ID: 18293418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The novel substituted pyrimidine, KP544, reduces motor deficits in the R6/2 transgenic mouse model of Huntington's disease.
    Dey ND; Boersen AJ; Myers RA; York LR; Bombard MC; Lu M; Sandstrom MI; Hulce VD; Lescaudron L; Dunbar GL
    Restor Neurol Neurosci; 2007; 25(5-6):485-92. PubMed ID: 18334766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease.
    Jenkins BG; Andreassen OA; Dedeoglu A; Leavitt B; Hayden M; Borchelt D; Ross CA; Ferrante RJ; Beal MF
    J Neurochem; 2005 Oct; 95(2):553-62. PubMed ID: 16135087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.